Fermion Technology and Simcere Pharmaceutical (HKEX: 2096) have announced a partnership to advance the development and commercialization of FZ002-037.
The clinical-stage treatment, which targets the SSTR4 receptor, is an oral candidate developed as a non-opioid therapy for pain management. It is the first drug of its kind in China and the second globally to reach the clinical stage.
Following successful completion of Phase I trials in China, Phase II studies for diabetic peripheral neuropathy are planned, with potential applications across chronic and acute pain conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze